ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Seattle Genetics has secured two antibody drug development deals. Genentech paid $60 million up front for exclusive rights to SGN-40, a humanized monoclonal antibody in Phase I and II clinical trials to treat a range of cancers. Seattle Genetics could earn up to $800 million in milestone payments, as well as royalties of more than 10% on sales of the drug. Genentech will cover all costs for development of the drug. Separately, Seattle Genetics will collaborate with Agensys to develop antibody-drug conjugates to treat cancer. The ADCs will combine Agensys antibodies with Seattle Genetics' conjugation technology.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X